Verve Therapeutics Faces Investor Lawsuit Following Clinical Trial Pause
Key Insights
Verve Therapeutics is facing a class action lawsuit alleging the company misled investors regarding the clinical trial for its cholesterol (search) medicine.
The lawsuit claims Verve overstated the potential of its drug delivery system and emphasized positive interim data without adequately warning of potential trial halts.
Enrollment in Verve's clinical trial was paused in April after a participant experienced an adverse reaction, including a low blood platelet count.
Verve Therapeutics Inc. is facing legal action from a shareholder who alleges the biotech firm misled investors concerning the clinical trial of its cholesterol (search) medication. The lawsuit, filed in the US District Court for the District of Massachusetts, accuses the Boston-based company of overstating the capabilities of its drug delivery system.
The plaintiff contends that Verve highlighted positive interim data without properly cautioning that the clinical trial could be halted due to adverse events. In April, Verve paused enrollment in the clinical trial after a participant experienced an adverse reaction, including a decrease in blood platelet count. The lawsuit claims that Verve's statements regarding its business, operations, and prospects were misleading.